LMU Klinikum Munich Treats World’s First Patient Using New ExacTrac Dynamic Patient Positioning & Monitoring System*

Brainlab, the digital medical technology company, announced today that LMU Klinikum Munich treated the first patient globally using ExacTrac Dynamic. Designed to streamline precision radiation therapy treatments, ExacTrac Dynamic combines surface, thermal and X-Ray tracking technologies for the treatment of a wide array of indications.

The patient presented a challenge for doctors at LMU Klinikum due to the location of the tumor and the traditional closed mask used for treatment. ExacTrac Dynamic delivers automated patient monitoring with multiple tracking technologies—surface, thermal and X-Ray—using a frameless cranial mask fixation system. The new Brainlab Cranial 4Pi Immobilization* and open-face mask system together with ExacTrac Dynamic enable a comfortable patient experience, without increasing the risk for excess radiation delivery to healthy tissue. ExacTrac Dynamic provides confidence for clinicians by ensuring the submillimetric precision needed to deliver a targeted treatment dose safely. By reducing the complexity of multiple systems, ExacTrac Dynamic helps providers streamline throughput and may lower the time that patients-at-risk spend in the hospital.

“Since the relatively small tumor was very close to the patient’s inner ear, it was a challenge to plan and treat,” said Professor Maximilian Niyazi, M.D., Deputy Director of the Clinic and Polyclinic for Radiation Therapy and Radiation Oncology at LMU Klinikum Munich. “Using ExacTrac Dynamic, we were able to consistently track the position of the tumor with high accuracy and very low latency to provide an extremely precise treatment, even with an open face mask.”

“I was nervous about the tight fitting mask and being immobilized on the treatment table. When Dr. Niyazi explained that LMU Klinikum had new technology with an open face mask system I was so relieved and knew I could move forward with the treatment that I needed. He showed me how ExacTrac Dynamic works, which really put my mind at ease. I felt confident that I was receiving a safe treatment in a way that wouldn’t cause me to panic.”

Professor Claus Belka, M.D., Director of the Clinic and Polyclinic for Radiation Therapy and Radiation Oncology at LMU Klinikum Munich added: “The system is very intuitive and flexible to use. It enables us to have constant real-time control with the automated interruption of treatment in the event of movements outside the pre-set tolerances that we’ve established for the patient. We really see the value that ExacTrac Dynamic brings to many different indications. For example, in complex radiosurgery for metastases in the spine, the system allows us to deliver highly precise, targeted dose by closely monitoring the internal anatomy with automated X-Ray monitoring. This is critical for spine treatments due to the proximity of the spinal cord to the target volume. Overall, the system helps deliver on our mission to provide patients with the best and most personalized care.”

“The first treatment at our long-time partner LMU Klinikum Munich is a major milestone in advancing patient care,” said Stefan Vilsmeier, President and CEO at Brainlab. “Healthcare digitization and automation through technologies like ExacTrac Dynamic are accelerating personalized patient treatment and the widespread adoption of best practice guidelines. Technologies like this are helping us deliver on our goal to make a positive impact on patient lives.”

* ExacTrac Dynamic is not commercially available in certain markets, including the United States. The information presented herein is general product information regarding ExacTrac Dynamic. The provision of the product information is not an attempt to market ExacTrac Dynamic in markets where the product is not commercially available, nor to solicit any orders for ExacTrac Dynamic in such markets, but rather is simply an opportunity for discussion. Commercial availability in all markets is contingent on the current release schedule and approval by the appropriate regulatory agencies.